Evidence map›Paper›PMID 26409751›Full record

Trial reportDrug and alcohol dependence2015

Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.

Frank J Vocci, Robert P Schwartz, Monique E Wilson, Michael S Gordon, Timothy W Kinlock, Terrence T Fitzgerald, Kevin E O'Grady, Jerome H Jaffe

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Frank J VocciFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA. Electronic address: fvocci@friendsresearch.org.
Robert P SchwartzFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Monique E WilsonFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Michael S GordonFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; Stevenson University, Department of Criminal Justice, 1525 Greenspring Valley Road, Stevenson, MD 21153, USA.
Timothy W KinlockFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Baltimore, School of Criminal Justice, College of Public Affairs, 1420 N. Charles Street, Baltimore, MD 21201, USA.
Terrence T FitzgeraldGlenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD 21212, USA.
Kevin E O'GradyUniversity of Maryland, 8082 Baltimore Avenue, College Park, MD 20740, USA.
Jerome H JaffeFriends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Maryland, School of Medicine, Department of Psychiatry, 110 S. Paca Street, Baltimore, MD 21201, USA.
Friends Research Institute · USCounseling Center · USStevenson University · USUniversity of Baltimore · USUniversity of Maryland, College Park · US

Funding

Buprenorphine for PrisonersR01DA021579 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI KINLOCK, TIMOTHY W · 2007 to 2011
$2.7M
NIDA NIH HHS R01 DA021579NIDA NIH HHS R01DA021579
6 · The paper itself

Abstract

backgroundIn a previously reported randomized controlled trial, formerly opioid-dependent prisoners were more likely to enter community drug abuse treatment when they were inducted in prison onto buprenorphine/naloxone (hereafter called buprenorphine) than when they received counseling without buprenorphine in prison (47.5% vs. 33.7%, p=0.012) (Gordon et al., 2014). In this communication we report on the results of the induction schedule and the adverse event profile seen in pre-release prisoners inducted onto buprenorphine.

methodThis paper examines the dose induction procedure, a comparison of the proposed versus actual doses given per week, and side effects reported for 104 adult participants who were randomized to buprenorphine treatment in prison. Self-reported side effects were analyzed using generalized estimated equations to determine changes over time in side effects.

resultsStudy participants were inducted onto buprenorphine at a rate faster than the induction schedule. Of the 104 (72 males, 32 females) buprenorphine recipients, 64 (37 males, 27 females) remained on medication at release from prison. Nine participants (8.6%) discontinued buprenorphine because of unpleasant opioid side effects. There were no serious adverse events reported during the in-prison phase of the study. Constipation was the most frequent symptom reported (69 percent).

conclusionOur findings suggest that buprenorphine administered to non-opioid-tolerant adults should be started at a lower, individualized dose than customarily used for adults actively using opioids, and that non-opioid-tolerant pre-release prisoners can be successfully inducted onto therapeutic doses prior to release.

Indexed as

PrisonersAdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationCounselingFemaleHumansMaleMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersPrisonsAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationBuprenorphine doseBuprenorphine inductionOpioid-dependent prisoners

Identifiers

PMID26409751
PMCPMC4633333
OpenAlexW2149683182

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.